Lateral epicondylitis: comparing ultrasound-guided tenotomy with or without amniotic membrane allograft injection.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING

Regenerative medicine Pub Date : 2023-05-01 DOI:10.2217/rme-2023-0027

Hirotaka Nakagawa, Kyungje Sung, Ken Mautner, Tabitha May, Walter I Sussman

引用次数: 0

Abstract

Aim: To evaluate the clinical response to augmenting ultrasound-guided tenotomy (USGT) with an amniotic membrane (AM) allograft injection. Design: Retrospective study. Materials & methods: Subjects underwent either a USGT (N = 16) or a combined USGT plus AM injection (N = 14). Results: Both groups demonstrated a significant reduction in pain from baseline starting after 2 weeks in the USGT plus AM group (p = 0.036) and after 8 weeks in the USGT group (p = 0.021). The reduction in pain was sustained for the entire duration of the study (52 weeks). There was no significant difference in pain levels at 26- or 52-week follow-up or patient satisfaction between the two groups. Conclusion: USGT with or without AM allograft injections results in a significant reduction in pain with high patient satisfaction.

查看原文本刊更多论文

外侧上髁炎:超声引导下的肌腱切开术与不注射同种异体羊膜的比较。

目的:评价超声引导下羊膜(AM)增强肌腱切开术(USGT)的临床疗效。设计:回顾性研究。材料与方法:受试者接受了USGT (N = 16)或USGT加AM注射(N = 14)。结果:两组疼痛均在USGT + AM组2周后(p = 0.036)和USGT组8周后(p = 0.021)从基线开始显著减轻。疼痛的减轻持续了整个研究期间(52周)。在26周或52周的随访中，两组患者的疼痛程度和患者满意度没有显著差异。结论:采用同种异体AM移植注射或不采用同种异体AM移植注射可显著减轻疼痛，患者满意度高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.